Zonisamide Inhibitor CAS No. 68291-97-4

Cat. No.	Name	Size	Price
KI0732	Zonisamide	10 mg	$154
	Zonisamide	25 mg	$272
	Zonisamide	100 mg	$592

Chemical Characteristic

Product Name	Zonisamide
Synonyms	AD 810, CI 912
CAS No.	68291-97-4
Molecular Weight	212.23
Formula	C₈H₈N₂O₃S
Chemical Name	1-(1,2-Benzoxazol-3-yl)methanesulphonamide
Smiles	C(S(=O)(=O)N)c1noc2c1cccc2
Chemical Structure

Biological activities

Zonisamide is a sulfonamide derivative exhibiting a broad spectrum of antiepileptic activity. Zonisamide inhibits voltage-dependent Na⁺ channels and Ca²⁺ channels of T-type.^[1] Zonisamide inhibits monoamine oxidase B (MAO-B) activity in vitro with an IC50 of 25 µM.^[2] The EC50 value for zonisamide-stimulated large-conductance Ca²⁺-activated K⁺ (BK(Ca)) channels is 34 µM. Zonisamide (30 µM) reversibly increases the amplitude of K⁺ outward currents in differentiated hippocampal 19-7 cells. Moreover, zonisamide at a concentration greater than 100 µM also reduces the amplitude of A-type K⁺ current in differentiated hippocampal 19-7 cells.^[3] In vivo, zonisamide treatment ( 40 mg/kg) increases dopamine turnover in the striatum of mice and common marmosets treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).^[4] Zonisamide also has neuroprotective effect against dopaminergic cell damage which may be mediated by the elevation of tyrosine hidroxylase (TH) activity on dopaminergic system after MPTP treatment in mice.^[5]

Protocols

In vitro: Zonisamide is dissolved in water.^[2]

References

[1] Sobieszek G, et al. Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003, 55(5): 683-689. [2] Sonsalla PK, et al. The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010, 221(2): 329-334. [3] Huang CW, et al. Activation by zonisamide, a newer antiepileptic drug, of large-conductance calcium-activated potassium channel in differentiated hippocampal neuron-derived H19-7 cells. J Pharmacol Exp Ther. 2007, 321(1): 98-106. [4] Yabe H, et al. Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. J Pharmacol Sci. 2009, 110(1): 64-68. [5] Yano R, et al. A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice. J Mol Neurosci. 2009, 39(1-2): 211-219.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.

KareBay^TM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.

About

KareBay^TM Biochem
Sitemap
Blog

Custom Services

Organic Synthesis
Peptide Synthesis
Antibody Production
Protein Expression
Bioconjugation Service
Immunoassry Service
Molecular Biology Services
Oligonucleotides Synthesis
RNA Synthesis Service
cGMP Peptide Synthesis Services
cGMP Organic Synthesis Services

Biochemical Products

Small Molecule Inhibitors
Bioactive Compounds
Primary Antibodies
Peptides
Amino Acids
Reagents
Fluorescent dyes
Intermediates
PCR

KareBay^TM Biochem, Inc.
11 Deer Park Drive, Suite 102A
Monmouth Junction, NJ 08852

Telephone

: 732-823-1545

Fax

: 732-823-1349

product@karebaybio.com
service@karebaybio.com
support@karebaybio.com